Last Price
54.13
Today's Change
-1.26 (2.27%)
Day's Change
51.70 - 55.63
Trading Volume
3,666,380
Market Cap
5 Billion
Shares Outstanding
110 Million
Avg Volume
3,818,232
Avg Price (50 Days)
56.83
Avg Price (200 Days)
50.01
PE Ratio
-58.20
EPS
-0.93
Earnings Announcement
23-Oct-2024
Previous Close
55.39
Open
55.47
Day's Range
51.7 - 55.63
Year Range
8.28 - 99.41
Trading Volume
3,686,291
1 Day Change
-2.27%
5 Day Change
-15.02%
1 Month Change
6.43%
3 Month Change
-3.32%
6 Month Change
-26.85%
Ytd Change
196.12%
1 Year Change
270.50%
3 Year Change
723.90%
5 Year Change
646.62%
10 Year Change
576.62%
Max Change
576.62%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.